18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in...
Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its BOTOX trade mark and for misleading or deceptive conduct. In...
Economy of court procedures primary factor in refusal to consider summary judgment application
Date: 22 September 2021Court: Federal Court of AustraliaJudge: Perram J Background Deco Australia Pty Ltd (Deco) alleged infringement by Aliwood Pty Ltd (Aliwood) of Innovation...
New .au domain names coming to Australia
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and organisations with an Australian presence will be able to...
The DABUS decision makes Australia look like a champion of innovation, not a chump
Originally published in the IAM Saturday Opinion on 11 September 2021. Australia was recently thrust into the global IP limelight when the Federal Court controversially...
Pearce IP BioBlast®: w/e 17 September 2021
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2...
Pearce IP BioBlast®: w/e 10 September 2021
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021....
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and support has actually been raised by Australia’s 2012 ‘Raising the...
Naomi Pearce recognised as a World Leading Patent Strategist by IAM
Pearce IP is proud to announce that Pearce IP’s Founding Principal and Executive Lawyer, Patent and Trade Mark Attorney, Naomi Pearce, has once again been recognised as a World...
Pearce IP BioBlast®: w/e 03 September 2021
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for...
Did pharmaceutical innovation contribute to the AI inventor controversy in Australia?
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI) system, DABUS, can be an...
Pearce IP BioBlast®: w/e 27 August 2021
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate...
Pearce IP BioBlast®: w/e 20 August 2021
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by...
Consider the Bar Raised for Sufficiency and Support: Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid
Date: 19 August 2021Court: Federal Court of AustraliaJudge: Burley J Background The ‘Bayer process’ has been used for over 130 years to extract alumina from bauxite to make...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when a patent covers two pharmaceutical substances of the...
Pearce IP BioBlast®: w/e 13 August 2021
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar trastuzumab) and pertuzumab administered as an admixture in...
PTEs in Australia – hard lessons for patentees from the Federal Court
Date: 12 August 2021Court: Federal Court of AustraliaJudge: Jagot J Background Under Australian law, a patent term extension (PTE) must be based on the “first regulatory...
Pearce IP BioBlast®: w/e 06 August 2021
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as...
Pearce IP BioBlast®: w/e 30 July 2021
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar development and manufacturing. 28 Jul 21 | Prestige BioPharma...
World-first decision: Artificial Intelligence recognised as a patent inventor under Australian law
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an artificial intelligence (AI) system, DABUS, can be an...
Naomi Pearce one of the world’s “best and brightest Women in IP”
Pearce IP is proud to announce that Principal and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been listed by WIPR Diversity as one of the world’s...
Pearce IP BioBlast®: w/e 23 July 2021
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of HLX04-O (proposed bevacizumab biosimilar) in the treatment of...
Blockchain technology gets a nod as patentable subject matter
Date: 21 July 2021Forum: Australian Patent OfficeDelegate: Ranganath Subbarayan Background Australian Patent Application 2018243625 (Application) in the name of Advanced New...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which measures adalimumab levels in blood. The test is able to return a...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.